دورية أكاديمية
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
| العنوان: | Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication |
|---|---|
| المؤلفون: | Miles D., Ciruelos E., Schneeweiss A., Puglisi F., Peretz-Yablonski T., Campone M., Bondarenko I., Nowecki Z., Errihani H., Paluch-Shimon S., Wardley A., Merot J. -L., Trask P., du Toit Y., Pena-Murillo C., Revelant V., Klingbiel D., Bachelot T., Bouzid K., Desmoulins I., Coudert B., Glogowska I., Ciruelos Gil E., Dalenc F., Ricci F., Dieras V., Kaufman B., Ferreira A., Mano M., Kalofonos H., Andreetta C., Montemurro F., Barrett S., Zhang Q., Mavroudis D., Matus J., Villarreal Garza C., Beato C., Ismael G., Hu X., Abdel Azeem H., Gaafar R., Perrin C., Kerbrat P., Ettl J., Paepke S., Hitre E., Lang I., Trudeau M., Verma S., Li H., Hoffmann O., Aktas B., Cariello A., Cruciani G., Tienghi A., Tondini C., Al-Twegieri T., Loman N., Laing R., Brain E., Fasching P., Lux M., Frassoldati A., Aziz Z., Salas J., Streb J., Krzemieniecki K., Wronski A., Garcia Garcia J., Menjon Beltran S., Cicin I., Schmid P., Gallagher C., Turner N., Tong Z., Boer K., Juhasz B., Horvath Z., Bianchini G., Gianni L., Curigliano G., Juarez Ramiro A., Susnjar S., Matos E., Sevillano E., Garcia Estevez L., Gokmen E., Uslu R., Wildiers H., Schutz F., Cruz M., Bourgeois H., von Schumann R., Stemmer S., Dominguez A., Morales-Vasques F., Wojtukiewicz M., Trifunovic J., Echarri Gonzalez M. J., Illarramendi Manas J., Martinez De Duenas E., Voitko N., Hicks J., Waters S., Barrett-Lee P., Wheatley D., De Boer R., Cocquyt V., Jerusalem G., Barrios C., Panasci L., Mattson J., Tanner M., Gozy M., Vasilopoulos G., Papandreou C., Revesz J., Battelli N., Benedetti G., Latini L., Gridelli C., Lazaro Leon J., Alarcon Company J., Arance Fernandez A., Barnadas Molins A., Calvo Plaza I., Bratos R., Gonzalez Martin A., Izarzugaza Peron Y., Klint L., Kovalev A., McCarthy N., Yeo B., Kee D., Thomson J., White S., Greil R., Wang S., Artignan X., Juhasz-Boess I., Rody A., Ngan R., Dourleshter F., Goldberg H., Doni L., Di Costanzo F., Ferrau F., Drobniene M., Aleknavicius E., Rashid K., Costa L., de la Cruz Merino L., Garcia Saenz J., Lopez R., Del Val Munoz O., Ozyilkan O., Azribi F., Jaafar H., Baird R., Verrill M., Beith J., Petzer A., Moreira de Andrade J., Bernstein V., Macpherson N., Rayson D., Saad Eldin I., Achille M., Augereau P., Muller V., Rasco A., Evron E., Katz D., Berardi R., Cascinu S., De Censi A., Gennari A., El-Saghir N., Ghosn M., Oosterkamp H. M., Van den Bosch J., Kukulska M., Kalinka E., Alonso J., Dalmau Portulas E., Del Mar Gordon Santiago M., Pelaez Fernandez I., Aksoy S., Altundag K., Senol Coskun H., Bozcuk H., Shparyk Y., Barraclough L., Levitt N., Panwar U., Kelly S., Rigg A., Varughese M., Castillo C., Fein L., Malik L., Stuart-Harris R., Singer C., Stoeger H., Samonigg H., Feng J., Cedeno M., Ruohola J., Berdah J. -F., Goncalves A., Orfeuvre H., Grischke E. -M., Simon E., Wagner S., Koumakis G., Papazisis K., Ben Baruch N., Fried G., Geffen D., Karminsky N., Peretz T., Cavanna L., Pedrazzioli P., Grasso D., Ruggeri E., D'Auria G., Moscetti L., Juozaityte E., Rodriguez Cid J., Roerdink H., Siddiqi N., Passos Coelho J., Arcediano Del Amo A., Garcia Garre E., Garcia Gonzalez M., Garcia-Palomo Perez A., Herenandez Perez C., Lopez Alvarez P., Lopez De Ceballos M. H., Martinez Janez N., Mele Olive M., McAdam K., Perren T., Dunn G., Humphreys A., Taylor W., Vera R., Kaen L., Andel J., Steger G., De Greve J., Huizing M., Hegg R., Joy A., Kuruvilla P., Sehdev S., Smiljanic S., Kutner R., Alexandre J., Grosjean J., Laplaige P., Largillier R., Maes P., Martin P., Pottier V., Christensen B., Khandan F., Luck H. -J., Zahm D. -M., Fountzilas G., Karavasilis V., Safra T., Inbar M., Ryvo L., Bonetti A., Seles E., Giacobino A., Chavarri Guerra Y., de Jongh F., van der Velden A., van Warmerdam L., Vrijaldenhoven S., Smorenburg C. H., Cavero M., Andres Conejero R., Oltra Ferrando A., Redondo Sanchez A., Ribelles Entrena N., Saura Grau S., Vinas Vilaro G., Bachmeier K., Beresford M., Butt M., Joffe J., Poole C., Woodings P., Chakraborti P., Yordi G., Woodward N., Nobre A., Luiz Amorim G., Califaretti N., Fox S., Robidoux A., Li E., Li N., Jiang J., Soria T., Padrik P., Lahdenpera O., Barletta H., Dohollou N., Genet D., Prulhiere K., Coeffic D., Facchini T., Vieillot S., Catala S., Teixeira L., Hesse T., Kuhn T., Ober A., Repp R., Schroder W., Pectasides D., Bodoky G., Kahan Z., Jiveliouk I., Rosengarten O., Rossi V., Alabiso O., Perez Martinez M., van de Wouw A. J., Smok-Kalwat J., Damasecno M., Augusto I., Sousa G., Saadein A., Abdelhafiez N., Abulkhair O., Anton Torres A., Corbellas Aparicio M., Llorente Domenech R., Florian Jerico J., Garcia Mata J., Gil Raga M., Galan Brotons A., Llombart Cussac A., Llorca Ferrandiz C., Martinez Del Prado P., Olier Garate C., Rodriguez Sanchez C., Sanchez Gomez R., Santisteban Eslava M., Soberino J., Vidal Losada Garcia M., Soto de Prado D., Torrego Garcia J., Vicente Rubio E., Garcia M., Murias Rosales A., Granstam Bjorneklett H., Narbe U., Jafri M., Rea D., Newby J., Jones A., Westwell S., Ring A., Alonso I., Rodriguez R. |
| المساهمون: | D. Mile, E. Ciruelo, A. Schneewei, F. Puglisi, T. Peretz-Yablonski, M. Campone, I. Bondarenko, Z. Nowecki, H. Errihani, S. Paluch-Shimon, A. Wardley, J.-. Merot, P. Trask, Y. du Toit, C. Pena-Murillo, V. Revelant, D. Klingbiel, T. Bachelot, K. Bouzid, I. Desmoulin, B. Coudert, I. Glogowska, E. Ciruelos Gil, F. Dalenc, F. Ricci, V. Diera, B. Kaufman, A. Ferreira, M. Mano, H. Kalofono, C. Andreetta, F. Montemurro, S. Barrett, Q. Zhang, D. Mavroudi, J. Matu, C. Villarreal Garza, C. Beato, G. Ismael, X. Hu, H. Abdel Azeem, R. Gaafar, C. Perrin, P. Kerbrat, J. Ettl, S. Paepke, E. Hitre, I. Lang, M. Trudeau, S. Verma, H. Li, O. Hoffmann, B. Akta, A. Cariello, G. Cruciani, A. Tienghi, C. Tondini, T. Al-Twegieri, N. Loman, R. Laing, E. Brain, P. Fasching, M. Lux, A. Frassoldati, Z. Aziz, J. Sala, J. Streb, K. Krzemieniecki, A. Wronski, J. Garcia Garcia, S. Menjon Beltran, I. Cicin, P. Schmid, C. Gallagher, N. Turner, Z. Tong, K. Boer, B. Juhasz, Z. Horvath, G. Bianchini, L. Gianni, G. Curigliano, A. Juarez Ramiro, S. Susnjar, E. Mato, E. Sevillano, L. Garcia Estevez, E. Gokmen, R. Uslu, H. Wildier, F. Schutz, M. Cruz, H. Bourgeoi, R. von Schumann, S. Stemmer, A. Dominguez, F. Morales-Vasque, M. Wojtukiewicz, J. Trifunovic, M.J. Echarri Gonzalez |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2021 |
| المجموعة: | The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| مصطلحات موضوعية: | HER2 positive, hormone receptor, metastatic breast cancer, overall survival, paclitaxel, pertuzumab, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocol, Female, Human, Neoplasm Recurrence, Local, Receptor, ErbB-2, Taxoid, Trastuzumab, Treatment Outcome, Breast Neoplasms, Settore MED/06 - Oncologia Medica |
| الوصف: | Background: The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination of pertuzumab, trastuzumab and docetaxel as standard first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive locally recurrent/metastatic breast cancer (LR/mBC). The multicentre single-arm PERtUzumab global SafEty (PERUSE) study assessed the safety and efficacy of pertuzumab and trastuzumab combined with investigator-selected taxane in this setting. Patients and methods: Eligible patients with inoperable HER2-positive LR/mBC and no prior systemic therapy for LR/mBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab and pertuzumab until disease progression or unacceptable toxicity. The primary endpoint was safety. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Prespecified subgroup analyses included subgroups according to taxane, hormone receptor (HR) status and prior trastuzumab. Exploratory univariable analyses identified potential prognostic factors; those that remained significant in multivariable analysis were used to analyse PFS and OS in subgroups with all, some or none of these factors. Results: Of 1436 treated patients, 588 (41%) initially received paclitaxel and 918 (64%) had HR-positive disease. The most common grade ≥3 adverse events were neutropenia (10%, mainly with docetaxel) and diarrhoea (8%). At the final analysis (median follow-up: 5.7 years), median PFS was 20.7 [95% confidence interval (CI) 18.9-23.1] months overall and was similar irrespective of HR status or taxane. Median OS was 65.3 (95% CI 60.9-70.9) months overall. OS was similar regardless of taxane backbone but was more favourable in patients with HR-positive than HR-negative LR/mBC. In exploratory analyses, trastuzumab-pretreated patients with visceral disease had the shortest median PFS (13.1 months) and OS (46.3 months). Conclusions: Mature results from PERUSE show a safety and efficacy profile consistent ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/34224826; info:eu-repo/semantics/altIdentifier/wos/WOS:000709095000007; volume:32; issue:10; firstpage:1245; lastpage:1255; numberofpages:11; journal:ANNALS OF ONCOLOGY; http://hdl.handle.net/2434/910142Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85111551739 |
| DOI: | 10.1016/j.annonc.2021.06.024 |
| الإتاحة: | https://doi.org/10.1016/j.annonc.2021.06.024Test http://hdl.handle.net/2434/910142Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.847D131B |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.annonc.2021.06.024 |
|---|